14 results about "Liver triglyceride" patented technology

The present application provides a polypeptide composition with anti-obesity effect, which is composed of capsaicin and polypeptides, and the amino acid sequence of the polypeptides comprises any one or more of SEQ ID NO. 1 to SEQ ID NO. 8. The polypeptides of sequences 1-8 are mixed uniformly at a mass ratio of 1-20:1-4:1-2:1-4:1:1:1:1, and the capsaicin is mixed with the mixed polypeptides at a ratio of 2-12:100 (w / w). The polypeptide composition proposed in the present application, in combination with capsaicin, not only promotes the weight loss effect of capsaicin, but also significantly reduces the fat index of the test mice after use, and can significantly reduce the total cholesterol concentration in the liver and the liver triglyceride concentration under a high-fat diet.

The invention discloses an adeno-associated virus overexpressing GPR110 and application of the adeno-associated virus in preparation of a medicine for treating metabolism-related steatohepatitis. The adeno-associated virus comprises a GPR110 gene sequence encoded and operably connected to a liver specific promoter TBG, an in-vivo experiment is carried out in a constructed MASH mouse model, and the result shows that the expression of the GPR110 gene in the liver tissue of the MASH mouse model is reduced, so that the GPR110 gene can be used as a biomarker and a therapeutic target of MASH, and the application of the GPR110 gene in the MASH mouse model is proven. According to the present invention, the MASH-related symptoms can be significantly improved through the AAV adeno-associated virus targeting liver specific overexpression GPR110, wherein the MASH-related symptoms comprise liver triglyceride content reducing, liver injury relieving, liver inflammation improving and liver fibrosis improving; the AAV-mediated GPR110 overexpression can effectively improve the MASH pathological process, and new intervention drugs and means can be provided for MASH treatment.

The invention relates to the technical field of poultry health assessment, in particular to a method for predicting and identifying the high fat deposition risk of the liver of a laying hen based on blood amino acid parameters. The method comprises the following steps: collecting a blood sample when the laying hen is in a metabolic state after absorption, detecting the total amino acid content and the alanine content in blood, and substituting blood parameters into a pre-established liver triglyceride prediction model to obtain the predicted liver triglyceride content, and comparing the prediction results to judge the high fat deposition risk of the liver of the laying hen. According to the method, the laying hens do not need to be slaughtered and sampled, the fat deposition state of the livers of the living laying hens can be rapidly evaluated, and the method is suitable for early screening and risk early warning of high fat deposition of the livers of the laying hens under the large-scale breeding condition.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

The invention provides application of a specific dihydroquinoline derivative in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific dihydroquinoline derivative significantly reduces the liver triglyceride level, so that alcohol-induced liver fatty degeneration is relieved, and the dihydroquinoline derivative has a good clinical transformation prospect.

The application provides use of a specific KPNA2 agonist and a combination of the specific KPNA2 agonist and other substances in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific KPNA2 agonist can significantly reduce liver triglyceride levels, thereby reducing alcohol-induced liver steatosis, and has good clinical conversion prospects, and the combination of the specific KPNA2 agonist and other substances has better effects.

The invention discloses a benzopyrone analogue as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The benzopyrone analogue has a structural formula as shown in a formula B in the specification. The invention also discloses a preparation method and application of the benzopyrone analogue. The invention provides a benzopyrone analogue with a new structure, and the benzopyrone analogue is named as ZDZ-553. The benzopyrone analogue can obviously reduce the content of triglyceride and cholesterol in the liver, also can obviously inhibit the inflammatory reaction of the liver of an NASH mouse, and can obviously reduce the mRNA level of inflammatory factors IL-6, IL-1beta and TNF-alpha in the liver. Therefore, the benzopyrone analogue disclosed by the invention can be used for preparing the medicine for resisting the non-alcoholic steatohepatitis.

The invention provides application of a specific KPNA2 agonist and application of the KPNA2 agonist and other substances in preparation of products for preventing or treating fatty liver. The specific KPNA2 agonist is found for the first time to remarkably reduce the level of liver triglyceride, so that alcohol-induced liver fatty degeneration is relieved, and the KPNA2 agonist has a good clinical transformation prospect and has a better effect when being combined with other substances.

The present invention relates to a composition comprising branched-chain amino acid metabolites for use in reducing hepatic triglycerides and / or improving glucose metabolism in an individual.

This invention provides the application of specific dihydroquinoline derivatives in the preparation of products for the prevention or treatment of fatty liver. This invention is the first to discover that specific dihydroquinoline derivatives significantly reduce liver triglyceride levels, thereby alleviating alcohol-induced hepatic steatosis, and possesses promising prospects for clinical translation.

The application relates to the technical field of biotechnology, gene function and application, and provides application of SNHG8 in preparation of a non-alcoholic fatty liver disease prevention and treatment drug. The drug can prevent and treat non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The application of SNHG8 in preparation of the non-alcoholic fatty liver disease prevention and treatment drug can effectively reduce the liver triglyceride content, relieve the increase of liver lipid accumulation and the up-regulation of lipid metabolism related protein expression induced by high-fat and high-cholesterol diet, so as to prevent, treat or relieve non-alcoholic fatty liver disease, and achieve the purpose of preventing and treating non-alcoholic fatty liver disease.

The application discloses application of a Solanum torvum extract in preparation of a medicine for preventing and treating non-alcoholic fatty liver and indications thereof, and the Solanum torvum extract comprises one or both of a Solanum torvum water extract and a Solanum torvum alcohol extract; the application is proved by experiments that the Solanum torvum alcohol extract can obviously reduce the weight of a non-alcoholic fatty liver NAFLD mouse; the Solanum torvum water extract can obviously reduce the inguinal white fat; the Solanum torvum extract can obviously reduce a liver weight / body weight index, a liver triglyceride (TG) content, liver lipid deposition, and liver function damage indexes, i.e., glutamic-oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT). The Solanum torvum extract can also reduce serum triglyceride (TG) and cholesterol (TC) levels of the mouse, improve lipid levels, and therefore has an important role in treating non-alcoholic fatty liver.